This perspective was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here

For the March cover article of its ASH Clinical News magazine, the American Society of Hematology dove into the weighty topic of “What’s a Life Worth and Who Gets to Decide?” Despite the provocatively misleading headline (cost-effectiveness analyses measure the benefit of a medicine, not the worthiness of a life), the article serves as a terrific explainer about why the entire US medical establishment is more mindful than ever about the need for cost-effectiveness research, and how ICER’s assessments are already being used to encourage not only fair drug pricing, but fair patient access too. ICER’s President Steve Pearson states:

“We are benefiting from a rich pipeline of innovative and wonderful new medications. The challenge is finding that sweet spot where we maintain access and affordability for individual patients and for the health-care system — because we will never have unlimited resources to spend on health — but also incentivize innovation and keep that pipeline flowing…. The real goal here is to use economic evaluations of cost-benefit or cost-effectiveness as a negotiating tool, especially where there’s limited competition. We’re not talking about rationing, but about providing a rational basis for pricing.”